Ranitidine's attitude towards banning doctors

Since the 2nd of this month, intermd, a knowledge sharing community of Korean doctors, has investigated 1021 doctors about the banning of ranitidine The results show that nearly half of doctors have encountered complaints from patients After the U.S FDA announced on September 13 that there was a low level of N-dimethylnitrosamine (NDMA) impurity in ranitidine, the Korean food and drug safety department (MFDs) found that the NDMA content in seven ranitidine raw materials exceeded the standard, and on September 26, it announced that it suspended the production and sale of all ranitidine used for the treatment of heartburn After that, intermd opened a survey to the main prescription ranitidine doctors, including 39% of physicians, 19% of family doctors, 18% of general practitioners, 7% of otolaryngologists, 6% of orthopedics, 5% of neurologists, etc The results showed that 49% of doctors complained about the long-term use of ranitidine, mainly including the lack of new prescription guidelines (14%), difficulties in re prescription of patients who had previously used ranitidine (13%) and concerns about alternative drugs (13%) However, doctors are also dissatisfied with the treatment of MFDs 41% of doctors think that after last year's valsartan crisis, regulators should control APIs more thoroughly 36% of doctors complain that only when foreign regulators take action, regulators start to take action, only 23% According to doctors, the regulatory response is relatively rapid and progressive compared with the previous valsartan incident For this ban, 65% of the doctors interviewed think that suspending all sales is an overreaction, which may cause confusion in the hospital, and 35% of the doctors think that the rapid response of the regulatory agencies is very good, after all, it is related to the public health With regard to the detection of NDMA impurities, 70% of doctors think that it is only the problem of ranitidine and drugs with similar structure, and 28% think that it is the problem of the whole H2 receptor antagonists.